Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Quince Therapeutics Inc QNCX

Healthcare Biotechnology
Quince Therapeutics, Inc. is a late-stage biotechnology company. The Company is engaged in unlocking the patient’s own biology to deliver life-changing therapeutics to those living with rare diseases. Its proprietary autologous intracellular drug encapsulation (AIDE) technology platform is a drug/device combination that uses an automated process designed to encapsulate a drug into the patient’s... see more

Recent & Breaking News (NDAQ:QNCX)

Cortexyme Announces $125 Million Private Placement

Business Wire February 5, 2020

Cortexyme Announces Publication of New Data Further Demonstrating the Therapeutic Potential of COR388, the Company's Lead Investigational Medicine

Business Wire January 30, 2020

Cortexyme Announces the Initiation of an Open-Label Extension Study for the GAIN Trial of COR388 in Alzheimer's Disease

Business Wire January 13, 2020

Cortexyme to Present at the 3rd Annual Neuroscience Innovation Forum on January 12, 2020

Business Wire January 8, 2020

Cortexyme to Present at the Evercore ISI 2nd Annual HealthCONx Conference on December 3, 2019

Business Wire November 26, 2019

Cortexyme Announces Third Quarter 2019 Financial Results and Provides Business Update

Business Wire November 12, 2019

Cortexyme Announces Oral Presentation on COR388 at Clinical Trials on Alzheimer's Disease 2019

Business Wire November 1, 2019

Cortexyme Announces European Screening Now Underway in the Phase 2/3 GAIN Trial

Business Wire September 26, 2019

Cortexyme to Present at the Canaccord Genuity Growth Conference on August 7th

Business Wire July 31, 2019

Cortexyme's Approach to Addressing a Key Underlying Cause of Alzheimer's Detailed at Alzheimer's Association International Conference 2019

Business Wire July 17, 2019

Cortexyme Announces Upcoming Data Presentations at the Alzheimer's Association International Conference 2019

Business Wire July 10, 2019

Cortexyme Expands Clinical Advisory Board With Key Clinical and Regulatory Experts

Business Wire June 19, 2019

Cortexyme to Present at National Academies Forum on Tuesday, June 11, 2019

Business Wire June 10, 2019